Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Avoca Quality Consortium and Longboat Clinical Partner to Deliver Clinical Trial Site Quality Management System (QMS) Tools to Industry Sponsors

Published

on

Reading Time: 3 minutes

DUBLIN–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/21CFRpart11?src=hash” target=”_blank”gt;#21CFRpart11lt;/agt;–Longboat Clinical is pleased to announce a new partnership with the
Avoca Quality Consortium (AQC) to make an extensive suite of quality
management tools available to hospitals and clinics participating in
clinical studies.

The AQC, a precompetitive collaborative comprised of nearly 100 pharma,
biotech, CRO, and clinical service provider companies, has been
committed to driving efficiency, increasing quality, and mitigating risk
in clinical trial execution through industry collaboration since 2011.
As part of the AQC’s dedication to improving quality and compliance at
investigative sites, the AQC developed a suite of peer reviewed quality
management tools that give new and experienced clinical trial sites a
solid basis to create a robust site-level QMS.

Longboat, an active AQC Member for over 5 years, is committed to
improving the conduct and quality in global clinical trials. Longboat
provides a clinical trial support platform with an integrated toolset
designed to ensure that site staff, patients, and study teams are
“virtually” guided at all times – creating an environment where protocol
compliance is instinctive, and giving all stakeholders the knowledge and
resources they need to conduct the trial.

Hospitals and clinics get involved in clinical trials with the greatest
of intentions to make cutting edge research available to their patients.
For good reason, the standard for data collection and systems management
is significantly higher for research studies, and institutions are
regularly audited by the Food & Drug Administration, European Medicines
Agency, and Institutional Review Boards, etc. to ensure the processes
for clinical trial execution and management are explicitly dated and
documented. This is a high burden for clinics where the primary focus is
patient care. This AQC/Longboat collaboration will make available a peer
reviewed framework to these sites to lower this barrier to entry.

Avoca Quote

“Improving quality and compliance at the site level is critical for the
success of all clinical trials,” states Patricia Leuchten, Founder and
CEO of The Avoca Group. “We’re proud to partner with Longboat on their
initiative to provide investigative sites access to the AQC’s
industry-leading site quality management tools.”

Longboat Quote

“Longboat is delighted to collaborate with the Avoca Group on this
initiative,” states John O’Sullivan, Chief Quality Officer at Longboat
Clinical. “Longboat is dedicated to driving the quality of clinical
trials, and as such, we are proud to use our platform to allow sites
globally to securely and speedily access the AQC’s suite of Quality
Management tools.”

About the Avoca Group

The Avoca Group leads the industry in GCP quality and compliance
solutions. With 20 years of experience providing research and consulting
services, Avoca merges deep institutional knowledge in the foundations
of good clinical practice with future-forward leadership in regulatory
compliance, quality management, and clinical operations across the
evolving clinical trials landscape. The Avoca Quality Consortium,
Avoca’s cross-functional collaborative, unites sponsors, CROs, and
clinical service providers to address challenges and maximize
opportunities to mitigate risk and improve both quality and execution in
clinical trials. More information at www.theavocagroup.com

About Longboat Clinical

Longboat is a clinical trials software company dedicated to generating
better study outcomes by creating a complete support structure for site
staff, patients, monitors, and study teams – where protocol compliance
becomes easy and instinctive. In the complex world of clinical
development, Longboat’s cloud-based site engagement platform empowers
clinical trial site staff to do the right thing at the right time while
engaging and supporting patients through their clinical trial journey.

More information at www.longboat.com

Contacts

Paddy Wall
[email protected]
+35361492111


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Cannabis

Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III

Published

on

Continue Reading

Humboldt

Humboldt Seed Company partners with Apollo Green to bring California cannabis genetics to the global marketplace

Published

on

humboldt-seed-company-partners-with-apollo-green-to-bring-california-cannabis-genetics-to-the-global-marketplace

Apollo Green to distribute Humboldt Seed Company clonal cannabis genetics to Germany, Portugal and Australia

SAN FRANCISCO, April 30, 2024 /PRNewswire/ — Humboldt Seed Company (HSC), California’s leading cannabis seed producer, has announced a partnership with Canadian-based Apollo Green to make eight breeder cuts available to researchers, licensed commercial cultivators and home growers in legal markets worldwide. This first-to-market clonal genetics release is a significant milestone and will expand access to distinctive, high-quality cannabis genetics in both established and emerging global markets including Germany, Portugal and Australia.

The curated, breeder-verified selection includes pioneering triploid genetics, such as OG Triploid and Donutz Triploid alongside the legendary cult classic Blueberry Muffin. Also available are All Gas OG with a THC content of 21% and four high-THC strains in the 30-35% range: Golden Sands, Guzzlerz, Jelly Donutz and Orange Creampop. These selections represent the top .01% from HSC’s extensive California pheno-hunting program.

Exports will begin in May under Apollo Green’s Canadian federal cannabis license. All shipments have Canadian phytosanitary certification, ensuring plants have been inspected, and are clean and free of pests.

“Access for all to quality genetics has been our core focus since the beginning,” said HSC Co-founder and Chief Science Officer, Benjamin Lind. “Our science-based approach to breeding aligns perfectly with Apollo Green’s high standards and we are excited to be able to extend these hand-selected cuts to a wider audience, especially at this pivotal time where we’re seeing positive regulatory changes globally.”

Oisin Tierney, Apollo Green Director of Business Development, said, “California has long been recognized for setting industry standards, and we are proud to play a role in bringing these esteemed genetics to cultivators worldwide. The triploids are especially noteworthy in terms of the unprecedented potential for enhanced plant vigor, higher yields, shorter flowering times and superior returns for solventless extraction.”

About Humboldt Seed Company

Established in 2001, Humboldt Seed Company is a Northern California heritage brand providing quality cannabis genetics to commercial cultivators and home growers in legalized states across the U.S. and international markets including Spain, Canada, Jamaica, South Africa, Colombia, France, Portugal, Greece, the UK, Malta and Thailand. With a focus on environmental and social justice, they combine traditional breeding and modern scientific practices in their strain development program. They have served the cannabis community for over two decades.

For more information visit https://humboldtseedcompany.com/.

About Apollo Green

Licensed since 2019, Apollo Green is Canada’s leader in cannabis genetics. The company’s mission is to provide an ever-growing bank of seeds and clones to medical patients and recreational consumers. Apollo Green provides clean, trusted cannabis seeds and clones, which are backed by the foremost tissue culture technology to reduce risks, costs and time-to-market for licensed producers around the world. Apollo Green is passionate about cannabis genetics. 

For more information visit https://apollogreen.com/.

Media contact
Jaana Prall
[email protected] 

Logo – https://mma.prnewswire.com/media/2328955/Humboldt_Seed_Company_Logo.jpg 

Cision View original content:https://www.prnewswire.co.uk/news-releases/humboldt-seed-company-partners-with-apollo-green-to-bring-california-cannabis-genetics-to-the-global-marketplace-302131618.html

Continue Reading

Cannabis

Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety

Published

on

Continue Reading
Advertisement

Latest news

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania